The risk of colitis was higher in patients treated with anti-CTLA-4 antibodies than in those treated with anti-PD-1 (ROR025 2.6) or anti-PD-L1 antibodies (ROR025 4.8). This evidence concerns the gene CTLA4 and colitis.